Bristol-Myers Squibb Raises Full-Year Guidance Amid Strong Portfolio Performance
Bristol-Myers Squibb (NYSE:BMY) raised its full-year guidance for 2026 following a strong second-quarter performance. CEO Christopher Boerner highlighted the company's robust growth, with sales in the growth portfolio increasing by 14%. The firm also noted that Eliquis is expected to grow between 20% and 25%, while the readout for milvexian AFib has been shifted to Q1 2027. The updated guidance reflects confidence in Bristol-Myers' ongoing performance, particularly driven by its key pharmaceutical products. The shift in timing for the milvexian AFib data suggests a strategic delay rather than an issue with development progress.
Tickers: $BMY
Topics: financial performance management commentary pharmaceuticals